LISAFEN 400 mg/3 ml Price

Overview

Welcome to Dwaey, specifically on LISAFEN 400 mg/3 ml Solution for injection page.
This medicine contains an important and useful components, as it consists of Ibuprofen lysine .
LISAFEN 400 mg/3 ml is available in the market in concentration 400 mg/3 ml and in the form of Solution for injection .

LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A is the producer of LISAFEN 400 mg/3 ml and it is imported from ITALY, The most popular alternatives of LISAFEN 400 mg/3 ml are listed downward .

Mode Of Action

Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.

Indication

• Rheumatoid arthritis
• Osteoarthritis
• Pain
• Fever
• Pericarditis
• Dysmenorrhea
• Patent ductus arteriosus
• Inflammation
• Musculoskeletal and joint disorders

Precaution

Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation. Lactation: Drug excreted into breast milk; use not recommended (American Academy of Pediatrics committee states that drug is compatible with nursing)

Side Effects

• 1-10% Dizziness (3-9%)
• Epigastric pain (3-9%)
• Heartburn (3-9%)
• Constipation (1-3%)
• Nausea (3-9%)
• Rash (3-9%)
• Tinnitus (3-9%)
• Edema (1-3%)
• Fluid retention (1-3%)
• Headache (1-3%)
• Vomiting (1-3%) <1% Acute renal failure (sometimes with acute tubular necrosis or hyperkalemia
• polyuria
• azotemia
• cystitis
• hematuria
• decreased creatinine clearance
• elevations in blood urea nitrogen (BUN) or creatinine without other manifestations of renal failure) Agranulocytosis
• Aplastic anemia
• Erythema multiforme
• Erythematous macular rashes
• Exfoliative dermatitis
• Hemolytic anemia (with or without positive direct antiglobulin test results)
• Neutropenia
• Thrombocytopenia (with or without purpura)
• Toxic epidermal necrolysis (Lyell syndrome) and photosensitivity reactions Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding
• ulceration and perforation.

Contra indication

Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy category: C; D in 3rd trimester or near delivery. At >30 weeks' gestation; may cause premature closure of ductus arteriosus